Japan· JP-4291431D2023
トラベクテジン
A trabectedin product containing トラベクテジン, registered in Japan by 大鵬薬品工業, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Trabectedin is registered in 17 of 19 countries.
Countries holding a registration under ATC L01CX01 (trabectedin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Trabectedin · ATC L01CX01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trabectedin costs, country by country.
Normalised to the WHO defined daily dose (0.13 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trabectedin · price per daily dose (0.13 mg)
USD · FX 28 Sept 2026
- CH Switzerland$226.47
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- トラベクテジン
- Manufacturer
- 大鵬薬品工業
- Country
- Japan (JP)
- ATC code
- L01CX01
- ATC class
- Trabectedin
- Defined daily dose
- 0.13 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
502 interactions on record for trabectedin.
Graded by severity as the source publishes them — 72 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trabectedin · interactions on record
502 records
- 72 severe
- 430 moderate
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01CX01
Trabectedin, as other registers publish it.
- United StatesEVDIApotex Corp.
- DenmarkTrabectedin "Teva"Teva B.V.
- DenmarkTrabectedin "Teva"Teva B.V.
- United KingdomTrabectedin 1mg powder for concentrate for solution for infusion vialsGenus Pharmaceuticals Ltd
- United KingdomTrabectedin 1mg powder for concentrate for solution for infusion vialsAccord-UK Ltd
- United KingdomTrabectedin 1mg powder for concentrate for solution for infusion vialsKent Pharma (UK) Ltd
- United KingdomTrabectedin 1mg powder for solution for infusion vialsSpecial Order
- United KingdomTrabectedin 250microgram powder for concentrate for solution for infusion vialsKent Pharma (UK) Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e8bfcf15-d440-4518-a65f-852b30739981 GET /v1/drugs/e8bfcf15-d440-4518-a65f-852b30739981?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "1mg1瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291431D2023",
"category": "注射薬",
"price_yen": 190625,
"generic_name": "トラベクテジン",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about trabectedin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.